Trial Profile

A pilot 12-week, multi-center, open-label clinical trial of LungFit™ GO in adult patients with chronic refractory NTM lung disease.

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 16 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nitric oxide (Primary)
Indications Mycobacterium avium complex infections; Nontuberculous mycobacterium infections
Focus Therapeutic Use
Acronyms LungFit HOME

Most Recent Events

10 Feb 2022 According to a Beyond Air media release, safety and efficacy data from the study will be presented at the American Thoracic Society conference 2022.
20 Oct 2021 Interim results (n=8, as of data cut off date September 6, 2021) published in the Beyond Air Media Release.
20 Oct 2021 According to a Beyond Air media release, the company expects complete safety and efficacy results to be reported in 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com